Tales of Antigen Evasion from CAR Therapy
- PMID: 27252092
- DOI: 10.1158/2326-6066.CIR-16-0089
Tales of Antigen Evasion from CAR Therapy
Abstract
Both T cells bearing chimeric antigen receptors and tumor-specific antibodies can successfully target some malignancies, but antigen escape can lead to relapse. Two articles in this issue of Cancer Immunology Research explore what effective countermeasures may prevent it. Cancer Immunol Res; 4(6); 473-473. ©2016 AACRSee articles by Zah et al., p. 498, and Rufener et al., p. 509.
©2016 American Association for Cancer Research.
Comment on
-
T Cells Expressing CD19/CD20 Bispecific Chimeric Antigen Receptors Prevent Antigen Escape by Malignant B Cells.Cancer Immunol Res. 2016 Jun;4(6):498-508. doi: 10.1158/2326-6066.CIR-15-0231. Epub 2016 Apr 8. Cancer Immunol Res. 2016. PMID: 27059623 Free PMC article.
-
Preserved Activity of CD20-Specific Chimeric Antigen Receptor-Expressing T Cells in the Presence of Rituximab.Cancer Immunol Res. 2016 Jun;4(6):509-19. doi: 10.1158/2326-6066.CIR-15-0276. Epub 2016 Apr 21. Cancer Immunol Res. 2016. PMID: 27197068 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
